ELICIT PLANT – Trademark Portfolio
Entity Type: 34
ELICIT PLANT holds 13 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 12 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 4 Nice Classification classes. Currently, 11 trademarks are registered and 2 are pending. Notable registered marks include BEST-A, ELICIT, ELISUN, ELIZEA, and ELIZON.
21 rue de Trion
F-69005 Lyon
Showing of trademarks Trademarks
Trademark Classifications
ELICIT PLANT's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does ELICIT PLANT have?
ELICIT PLANT has 13 U.S. trademarks filed with the USPTO. Of these, 11 registered, 2 pending.
What trademark classes does ELICIT PLANT file in?
ELICIT PLANT files trademarks across 4 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are ELICIT PLANT's most well-known trademarks?
ELICIT PLANT's registered trademark portfolio includes well-known marks such as BEST-A, ELICIT, ELISUN, ELIZEA, and ELIZON. These are among 11 currently registered trademarks in the portfolio.
What is ELICIT PLANT's trademark registration success rate?
ELICIT PLANT has a 100% trademark registration rate, with 11 out of 11 resolved applications resulting in successful registration. Currently, 2 applications are pending review.